FDA panel backs Heplisav-B, wants rigorous postmarketing study

Dynavax Technologies Corp. (NASDAQ:DVAX) jumped $7.45 (81%) to $16.70 in after-hours trading on Friday after FDA's Vaccines and Related Biological Products Advisory Committee voted 12 to one, with three abstentions, that available safety data support the

Read the full 369 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE